451 reports of this reaction
4.8% of all ZINC OXIDE reports
#2 most reported adverse reaction
MACULAR DEGENERATION is the #2 most commonly reported adverse reaction for ZINC OXIDE, manufactured by MONAT GLOBAL CORP. There are 451 FDA adverse event reports linking ZINC OXIDE to MACULAR DEGENERATION. This represents approximately 4.8% of all 9,433 adverse event reports for this drug.
Patients taking ZINC OXIDE who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is moderately reported among ZINC OXIDE users, representing a notable but not dominant share of adverse events.
In addition to macular degeneration, the following adverse reactions have been reported for ZINC OXIDE:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 451 FDA reports for ZINC OXIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 4.8% of all adverse event reports for ZINC OXIDE, making it one of the most commonly reported side effect.
If you experience macular degeneration while taking ZINC OXIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.